Home » Healthcare » Pharmaceuticals » Post-Traumatic Stress Disorder Therapeutics Market

Post-Traumatic Stress Disorder Therapeutics Market By Drug Class (Antidepressants, Anti-Anxiety Drugs, Other Drug Classes, Pipeline Candidate) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Summary
Table Of Content

Industry Outlook

The global post-traumatic stress disorder therapeutics market is expected to reach 10,679.5 million dollars by 2026, with a CAGR of 4.5% during the forecast period from 2018 to 2026. Antidepressants, including SSRIs (Zoloft and Paxil), are among the first lines of treatment for PTSD. They dominated the global market in 2017 and are projected to retain their dominance during the forecast period. North America dominated the PTSD therapeutics market in 2017, accounting for more than half of the market. Higher awareness about healthcare and treatment among the general population and a better rate of self-reporting are some macro factors contributing to the dominance of North America in the global market. Post-traumatic stress disorder (PTSD) is a vastly prevalent disorder but a rarely recognized syndrome that is characterized by some serious reactions such as fear, helplessness, and horror. According to the Diagnostic and Statistical Manual of Mental Disorders, PTSD is categorized as acute if symptoms occur within three months of the trauma and chronic if symptoms occur between three and six months after the trauma.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Post-traumatic stress disorder is classified as an anxiety disorder, and symptoms of PTSD can develop either immediately following a traumatic event or over the course of time. The symptoms of PTSD comprise abnormal mood swings, avoidance of stressful incidents, and so on. PTSD occurs at any age, irrespective of gender; however, the prevalence of PTSD is higher in women. As reported by PTSD United, an estimated one in every eight women develops PTSD in a lifetime, thus making females twice as likely to develop PTSD as males. The prevalence of PTSD in the United States is 3.5%.

The growing prevalence of post-traumatic stress disorder is the chief factor driving the global post-traumatic stress disorder drug market. An increase in events such as wars, combat, and interpersonal violence has been a major contributor to the growing prevalence of PTSD. Factors such as governments’ increasing emphasis on rehabilitation initiatives for treating war veterans have also aided the rise in demand for PTSD therapeutics.

The United States dominated the global PTSD therapeutics market. Moreover, the domicile of prominent players and the swift approval of drugs in the region ensure the dominance of North America. Europe is identified as the second largest market due to the growing patient pool, greater awareness regarding the availability and efficacy of therapeutics, and initiatives from government and non-government organizations to strengthen and develop healthcare infrastructure along with a favorable reimbursement system. The awareness of PTSD is low in the Asia Pacific region compared to North America and Europe due to the lack of diagnosis and criticality of mental disorders in the general population.

Market Synopsis

Antidepressant drugs are leading the post-traumatic stress disorder therapeutics market.

Currently, antidepressants, including SSRIs (Zoloft and Paxil), are among the first lines of treatment for PTSD. They dominated the global market in 2017 and are projected to retain their dominance during the forecast period from 2018 to 2026. Moreover, the prevalence of diseases is rising due to the increasing number of accidents and violence worldwide, and the global PTSD therapeutics market is expected to grow during the forecast period from 2018 to 2026.

Periods of History and Forecast

2016 : historic year.

2017: Base Year

2018-2026: Forecast Period

This comprehensive study offers an analysis of every segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each segment is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

A post-traumatic stress disorder therapeutics market study offers the existing market dynamics along with a quantitative analysis of the global market. The report elucidates the detailed outline of the global post-traumatic stress disorder therapeutics market by classifying the market in terms of drug class and geography. The objective of publishing this extensive research report is to support healthcare professionals and market investors in making strategic initiatives and better conclusions in the post-traumatic stress disorder therapeutics market.

Drug Class Segment (2016-2026; US Dollar Millions)

Antidepressants

SSRIs
SNRIs
MAO Inhibitors
Tricyclic Antidepressants

Anti-anxiety Drugs

Beta-blockers
Benzodiazepines

Other Drug Classification

Alpha-1 and Alpha-2 Receptor Antagonists
Atypical Antipsychotics
Anticonvulsants

Pipeline candidates (qualitative information)

SRX 246 (Phase II)
BNC 210 (Phase II)
Tonmya (Phase II)

Geography Segment (2016-2026; millions of dollars)

North America

United States
Canada

Europe

United Kingdom
Germany
Rest of Europe

Asia-Pacific (APAC)

Japan
China
Rest of APAC

Latin America (LATAM)

Mexico
Brazil
Rest of LATAM

Middle East and Africa (MEA)

GCC
Rest of the Middle East and Africa

This comprehensive study further describes the major qualitative market assessment factors, including main market drivers, market trends, and restraints, to help in a better understanding of the global post-traumatic stress disorder therapeutics market. Every market assessment factor, including market drivers, challenges, and opportunities, is widely explained considering the existing market situation. This study fully maps the market players based on their strategies, market initiatives, business strengths, and product offerings. Moreover, the report offers an attractive investment proposal based on the widespread geographical research. The main players profiled in the study include Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd., Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd., Tonix Pharmaceuticals Holding Corp., and Apotex, Inc., among others.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

What are the current market trends in the post-traumatic stress disorder therapeutics market and the most valuable opportunities for the players?
How does the regulatory framework affect global as well as regional markets?
Which drug class is the most prevalent in the PTSD treatment market?
How does the FDA’s approval of products affect the global market?
What are the trends and market sizes in emerging markets such as Japan, Mexico, and Brazil?
Which is the largest and fastest-growing regional market?
Which is the largest segment by drug class in the post-traumatic stress disorder therapeutics market?
Which is the fastest-growing segment by drug class in the post-traumatic stress disorder therapeutics market?
Market assessment in terms of value.
analysis of market strategies and competitive landscapes

Chapter 1. Preface

1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2017 (US$ Mn)
2.2. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Post-Traumatic Stress Disorder Therapeutics Market Overview, 2016 – 2026 (US$ Mn)
3.1. Overview
3.2. Market Drivers
3.2.1. Growing Events of Violence and Wars
3.3. Challenges
3.3.1. Lack of Timely Diagnosis and Access to Care
3.3.2. Risk of Side Effects
3.4. Opportunities
3.4.1. Promising Pipeline Candidates
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Market Competition Assessment, 2017

Chapter 4. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Antidepressants
4.2.1. SSRIs
4.2.2. SNRIs
4.2.3. MAO Inhibitors
4.2.4. Tricyclic Antidepressants
4.3. Anti-anxiety Drugs
4.3.1. Beta-blockers
4.3.2. Benzodiazepines
4.4. Other Drug Classes
4.4.1. Alpha-1 & Alpha-2 Receptor Antagonists
4.4.2. Atypical Antipsychotics
4.4.3. Anticonvulsants
4.5. Pipeline Candidates (Qualitative Information)
4.5.1. SRX 246 (Phase II)
4.5.2. BNC 210 (Phase II)
4.5.3. Tonmya (Phase II)

Chapter 5. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America
5.2.1. North America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.2.3. North America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.2.4. North America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.2.5. North America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.2.5.1. U.S.
5.2.5.2. Canada
5.3. Europe
5.3.1. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.3.3. Europe Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.3.4. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.3.5. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.3.5.1. U.K.
5.3.5.2. Germany
5.3.5.3. Rest of Europe
5.4. Asia Pacific
5.4.1. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.4.3. Asia Pacific Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.4.4. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.4.5. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.4.5.1. Japan
5.4.5.2. China
5.4.5.3. Rest of APAC
5.5. Latin America
5.5.1. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.5.3. Latin America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.5.4. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.5.5. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.5.5.1. Brazil
5.5.5.2. Mexico
5.5.5.3. Rest of Latin America
5.6. Middle East & Africa
5.6.1. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.6.3. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.6.4. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.6.5. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Region, 2016 – 2026 (US$ Mn)
5.6.5.1. GCC
5.6.5.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Pfizer, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. GlaxoSmithKline plc
6.3. Otsuka Pharmaceutical Co., Ltd
6.4. Novartis AG
6.5. AstraZeneca Plc
6.6. Azevan Pharmaceuticals, Inc.
6.7. Bionomics Ltd.
6.8. Tonix Pharmaceuticals Holding Corp.
6.9. Apotex, Inc.

List of Figures

FIG. 1 Global Post-Traumatic Stress Disorder Therapeutics Market: Research Methodology
FIG. 2 Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2017 (US$ Mn)
FIG. 3 Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017 (US$ Mn)
FIG. 4 Annual Number of Deaths in Combatants, 1945 to 2010
FIG. 5 Attractive Investment Proposition: Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017
FIG. 6 Competitive Landscape, by Key Players, 2017
FIG. 7 Global SSRIs Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 8 Global SNRIs Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 9 Global MAO Inhibitors Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 10 Global Tricyclic Antidepressants Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 11 Global Beta-Blockers Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 12 Global Benzodiazepines Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 13 Global Alpha-1 & Alpha-2 Receptor Antagonists Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 14 Global Atypical Antipsychotics Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 15 Global Anticonvulsants Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)

List of Tables

TABLE 1 Global Post-Traumatic Stress Syndrome Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 2 Global Antidepressants Market for Post-Traumatic Stress Syndrome, 2016–2026 (US$ Mn)
TABLE 3 Global Anti-anxiety Drugs Market for Post-Traumatic Stress Syndrome, 2016–2026 (US$ Mn)
TABLE 4 Global Other Drug Classes Market for Post-Traumatic Stress Syndrome, 2016–2026 (US$ Mn)
TABLE 5 Global Post-Traumatic Stress Syndrome Therapeutics Market, by Geography, 2016–2026 (US$ Mn)
TABLE 6 North America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 7 North America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 8 North America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 9 North America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 10 North America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 11 Europe Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Europe Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 13 Europe Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 14 Europe Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 15 Europe Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 16 Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 17 Asia Pacific Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 18 Asia Pacific Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 19 Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 20 Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 21 Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 22 Latin America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 23 Latin America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 24 Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 25 Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 26 Middle East & Africa Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 27 Middle East & Africa Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 28 Middle East & Africa Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 29 Middle East & Africa Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 30 Middle East & Africa Post-Traumatic Stress Disorder Therapeutics Market, by Region, 2016–2026 (US$ Mn)
TABLE 31 Pfizer, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 32 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 33 Otsuka Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 34 Novartis AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 35 AstraZeneca Plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 36 Azevan Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 37 Bionomics Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 38 Tonix Pharmaceuticals Holding Corp.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 39 Apotex Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Post-Traumatic Stress Disorder Therapeutics Market?

The market for Post-Traumatic Stress Disorder Therapeutics Market is expected to reach US$ 10,679.5 Bn By 2026.

What is the Post-Traumatic Stress Disorder Therapeutics Market CAGR?

The Post-Traumatic Stress Disorder Therapeutics Market is expected to see significant CAGR growth over the coming years, at 4.5%.

What is the Forecast period considered for Post-Traumatic Stress Disorder Therapeutics Market?

The report is forecasted from 2018-2026.

What is the base year considered for Post-Traumatic Stress Disorder Therapeutics Market?

The base year of this report is 2017.

Who are the major players in this market?

Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd., Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd., Tonix Pharmaceuticals Holding Corp., and Apotex, Inc.are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –